Biological modification strategies following marrow ablative, high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue (AHSCR) for pediatric brain tumors

2010 ◽  
Vol 54 (4) ◽  
pp. 654-656 ◽  
Author(s):  
Stergios Zacharoulis ◽  
Susan Chi ◽  
Richard Kadota ◽  
Mark Kieran
Keyword(s):  
Stem Cell ◽  
Brain Tumors ◽  
Hematopoietic Stem Cell ◽  
Pediatric Brain Tumors ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue ◽  
Biological Modification ◽  
Pediatric Brain

scholarly journals High-Dose Chemotherapy with Autologous Hematopoietic Stem-Cell Rescue for Pediatric Brain Tumor Patients: A Single Institution Experience from UCLA

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Eduard H. Panosyan ◽  
Alan K. Ikeda ◽  
Vivian Y. Chang ◽  
Dan R. Laks ◽  
Charles L. Reeb ◽  
...  
Keyword(s):  
Stem Cell ◽  
Brain Tumors ◽  
Hematopoietic Stem Cell ◽  
Germ Cell Tumors ◽  
Pediatric Brain Tumors ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue ◽  
Pediatric Brain

Background. Dose-dependent response makes certain pediatric brain tumors appropriate targets for high-dose chemotherapy with autologous hematopoietic stem-cell rescue (HDCT-AHSCR).Methods. The clinical outcomes and toxicities were analyzed retrospectively for 18 consecutive patients ≤19 y/o treated with HDCT-AHSCR at UCLA (1999–2009).Results. Patients' median age was 2.3 years. Fourteen had primary and 4 recurrent tumors: 12 neural/embryonal (7 medulloblastomas, 4 primitive neuroectodermal tumors, and a pineoblastoma), 3 glial/mixed, and 3 germ cell tumors. Eight patients had initial gross-total and seven subtotal resections. HDCT mostly consisted of carboplatin and/or thiotepa ± etoposide (n=16). Nine patients underwent a single AHSCR and nine ≥3 tandems. Three-year progression-free and overall survival probabilities were 60.5% ± 16 and 69.3% ± 11.5. Ten patients with pre-AHSCR complete remissions were alive/disease-free, whereas 5 of 8 with measurable disease were deceased (median followup: 2.3 yrs). Nine of 13 survivors avoided radiation. Single AHSCR regimens had greater toxicity than ≥3 AHSCR (P<.01).Conclusion. HDCT-AHSCR has a definitive, though limited role for selected pediatric brain tumors with poor prognosis and pretransplant complete/partial remissions.

scholarly journals High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California

2000 ◽  
Vol 6 (5) ◽  
pp. 496-505 ◽  
Author(s):  
Lloyd E. Damon ◽  
Wendy W. Hu ◽  
Keith E. Stockerl-Goldstein ◽  
Karl G. Blume ◽  
Jeffrey L. Wolf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue ◽  
Cancer Experience

High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease

1993 ◽  
Vol 66 (5) ◽  
pp. 251-256 ◽  
Author(s):  
N. Schmitz ◽  
B. Glass ◽  
P. Dreger ◽  
T. Haferlach ◽  
H. -A. Horst ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue

High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma

2010 ◽  
pp. n/a-n/a ◽  
Author(s):  
Ira J. Dunkel ◽  
Helen S.L. Chan ◽  
Rima Jubran ◽  
Guillermo L. Chantada ◽  
Stewart Goldman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue
Sign in / Sign up

Export Citation Format

Share Document